
Sign up to save your podcasts
Or


Lori Ellis, head of insights at BioSpace, discusses some of the recent events and topics that are buzzing around BIO and DIA in 2025 with Rich Daly, CEO of Catalyst Pharmaceuticals, Peter Ronco, CEO of Emmes Corporation, and Phil Vanek, founder of Redline Bio Advisors. They address funding, the partnering market, AI, and also the recent FDA and CGT roundtable discussion.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Peter Ronco, CEO, Emmes
Phil Vanek, Founder, Redline Bio Advisors; Chief Commercial Officer, ISCT; Entrepreneur in Residence, Georgetown University School of Medicine
Richard Daly, President & Chief Executive Officer, Catalyst Pharmaceuticals
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
By BioSpace4.9
1313 ratings
Lori Ellis, head of insights at BioSpace, discusses some of the recent events and topics that are buzzing around BIO and DIA in 2025 with Rich Daly, CEO of Catalyst Pharmaceuticals, Peter Ronco, CEO of Emmes Corporation, and Phil Vanek, founder of Redline Bio Advisors. They address funding, the partnering market, AI, and also the recent FDA and CGT roundtable discussion.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Peter Ronco, CEO, Emmes
Phil Vanek, Founder, Redline Bio Advisors; Chief Commercial Officer, ISCT; Entrepreneur in Residence, Georgetown University School of Medicine
Richard Daly, President & Chief Executive Officer, Catalyst Pharmaceuticals
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

91,297 Listeners

30,609 Listeners

43,687 Listeners

8,801 Listeners

977 Listeners

4,420 Listeners

1,173 Listeners

1,993 Listeners

56,944 Listeners

9,556 Listeners

337 Listeners

6,097 Listeners

6,592 Listeners

34 Listeners

21 Listeners